StreetInsider.com News Articles

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP

Fri, 15 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260515/26504681.html

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP

Fri, 15 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260515/26504681.html

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Bellevue Group AG

Fri, 15 May 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26503903.html

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Bellevue Group AG

Fri, 15 May 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26503903.html

Celldex Therapeutics (CLDX) PT Raised to $54 at Wells Fargo

Wed, 13 May 2026 06:04:18 -0400

Wells Fargo analyst Derek Archila raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $54.00 (from $38.00) while maintaining a Overweight rating.

The analyst comments "We are getting more constructive on CLDX ahead of barzo's PN readout in mid-2026. We believe the Street underappreciates the biological rationale, supportive Ph1b data and the role mast-cell depletion may play in the PN itch-scratch cycle. Barzo's Ph2 PN program appears well de-risked. KIT-driven mast cell depletion may disrupt the itch scratch cycle with added rationale from Nemluvio, which inhibits IL-31, a pruritogenic cytokine produced by mast cells and is approved in PN. Supportive

Celldex Therapeutics (CLDX) PT Raised to $54 at Wells Fargo

Wed, 13 May 2026 06:04:18 -0400

Wells Fargo analyst Derek Archila raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $54.00 (from $38.00) while maintaining a Overweight rating.

Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP

Tue, 12 May 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26475180.html

Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP

Tue, 12 May 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26475180.html

Celldex Therapeutics (CLDX) PT Raised to $48 at Barclays

Fri, 08 May 2026 04:05:17 -0400

Barclays analyst Etzer Darout raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $48.00 (from $45.00) while maintaining a Overweight rating.

Celldex (CLDX) Tops Q1 EPS by 1c

Thu, 07 May 2026 17:45:11 -0400

Celldex (NASDAQ: CLDX) reported Q1 EPS of ($1.18), $0.01 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $15 thousand versus the consensus estimate of $874.9 thousand.

For earnings history and earnings-related data on Celldex (CLDX) click here.

Form 10-Q Celldex Therapeutics, For: Mar 31

Thu, 07 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260507/26453132.html

Form 10-Q Celldex Therapeutics, For: Mar 31

Thu, 07 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260507/26453132.html

Form 8-K Celldex Therapeutics, For: May 07

Thu, 07 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260507/26452670.html

Form 8-K Celldex Therapeutics, For: May 07

Thu, 07 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260507/26452670.html

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:01:00 -0400

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027
Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling
Phase 1 CDX-622 proof of mechanism study in asthma ongoing
2026 expected to deliver multiple key data readouts across the pipeline
Raised $345 million in gross proceeds from a follow-on public offering, closed in April 2026